Atreca, Inc. - (BCEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
BCEL Stock Price Chart Interactive Chart >
BCEL Price/Volume Stats
| Current price | $1.84 | 52-week high | $10.73 |
| Prev. close | $1.69 | 52-week low | $1.56 |
| Day low | $1.66 | Volume | 229,300 |
| Day high | $1.86 | Avg. volume | 1,325,746 |
| 50-day MA | $2.58 | Dividend yield | N/A |
| 200-day MA | $3.83 | Market Cap | 69.48M |
Atreca, Inc. - (BCEL) Company Bio
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.
Latest BCEL News From Around the Web
Below are the latest news stories about Atreca Inc that investors may wish to consider to help them evaluate BCEL as an investment opportunity.
Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will report fourth quarter 2021 financial results and members of the company’s management team will host a year-end conference call, which will include an update on progress in the ongoing ATRC-101 |
Atreca, Inc. (BCEL) Upgraded to Buy: Here's What You Should KnowAtreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Atreca to Present Anti-SARS-CoV-2 Antibody Discoveries at Keystone Symposia Conference: Antibodies as DrugsSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present data on broadly neutralizing SARS-CoV-2 antibodies discovered by the company at the upcoming Keystone Symposia Conference: Antibodies as Drugs, being held January 30 – February 2, 2022 |
Goldman Sachs Group Inc. Lowers Stock Holdings in Atreca, Inc. (NASDAQ:BCEL)Goldman Sachs Group Inc. cut its stake in shares of Atreca, Inc. (NASDAQ:BCEL) by 63.0% in the 2nd quarter, Holdings Channel reports. The fund owned 99,913 shares of the companys stock after selling 170,340 shares during the quarter. Goldman Sachs Group Inc.s holdings in Atreca were worth $851,000 as of its most recent filing with [] |
Atreca Inc. (BCEL): What Is Good About Stock?Atreca Inc. (NASDAQ:BCEL) has seen 1.87 million shares traded in the last trading session. The company, currently valued at $134.16M, closed the last trade at $3.59 per share which meant it lost -$0.36 on the day or -9.11% during that session. The BCEL stock price is -465.18% off its 52-week high price of $20.29 and Atreca Inc. (BCEL): What Is Good About Stock? Read More » |
BCEL Price Returns
| 1-mo | -23.97% |
| 3-mo | N/A |
| 6-mo | -60.93% |
| 1-year | -79.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.27% |
| 2021 | -81.24% |
| 2020 | 4.40% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...